Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

DN-tTIS for Post-Stroke Motor Recovery

16 novembre 2026 mis à jour par: Tang Zhouping, Tongji Hospital

Safety and Efficacy of Non-invasive Temporal Interference Electrical Stimulation of the Cerebellar Dentate Nucleus for Upper Limb Motor Recovery in Chronic Stroke: A Preliminary Study

This study aims to explore a new, non-invasive treatment to help patients recover upper limb motor function after a stroke. Many stroke survivors experience long-term movement difficulties, and standard physical therapies may not always be effective, especially for those with severe motor impairments. Previous research suggests that stimulating a specific deep brain region called the cerebellar dentate nucleus can promote motor recovery, but traditional methods require invasive surgery.

In this study, researchers will investigate a novel technology called Temporal Interference (TI) electrical stimulation. TI allows researchers to safely and painlessly stimulate deep brain areas from the scalp without any surgery or implanted electrodes. The research team will enroll 10 patients who experienced a stroke 1 to 3 years ago and still have moderate to severe upper limb weakness. Participants will receive TI stimulation therapy 5 times a week for 4 weeks. Before, during, and after the treatment period, the researchers will use clinical physical assessments, brain imaging (fMRI), and non-invasive brain monitoring (EEG and fNIRS) to evaluate whether this treatment is safe, feasible, and effective for improving upper limb movement in chronic stroke survivors.

Aperçu de l'étude

Statut

Pas encore de recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

10

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • * Meets the diagnostic criteria for "stroke" in the "Key Points for Diagnosis of Major Cerebrovascular Diseases in China 2019", and confirmed by cranial CT or MRI.

    • First-ever stroke, with a disease duration of 1 year to 3 years (inclusive).
    • Age between 18 and 70 years old (inclusive).
    • Ischemic stroke in the territory of the unilateral middle cerebral artery, without affecting the cerebellum, thalamus, and brainstem.
    • Stable medical and neurological conditions, as determined by the investigator based on medical history, physical, and neurological examinations.
    • Residual moderate to severe unilateral upper limb hemiplegia, defined as an Upper Extremity Fugl-Meyer Assessment (FMA-UE) score of ≤ 50 on the affected side.
    • A score of ≥ 1 in at least one of the following FMA-UE sub-items: elbow flexion, elbow extension, or finger grasp.
    • Modified Rankin Scale (mRS) score < 4.
    • No spasticity or moderate spasticity in the affected limb, defined as a Modified Ashworth Scale (MAS) score < 4 in any region of the affected limb (shoulder internal rotators and adductors, elbow flexors, wrist flexors, or finger flexors).
    • Mini-Mental State Examination (MMSE) score ≥ 24.

Exclusion Criteria:

  • Primary hemorrhagic stroke or severe hemorrhagic transformation.

    • Presence of any other progressive neurological or somatic diseases impairing the target limb function, other than stroke.
    • Moderate to severe unilateral spatial neglect or anosognosia involving the affected side of the body.
    • Presence of any other neurological diseases that may compromise the safety of study participation, including central nervous system vasculitis, intracranial tumors, intracranial aneurysms, multiple sclerosis, or arteriovenous malformations.
    • Pain in the affected limb, defined as a pain score of ≥ 5 on the 0-10 Numeric Rating Scale (NRS).
    • Severe sensory impairment, demonstrated by a score of 2 on the National Institutes of Health Stroke Scale (NIHSS) sensory item (Item 8).
    • Occurrence of seizures since the stroke, regardless of the use of antiepileptic drugs.
    • Diagnosis of underlying seizure disorder or epilepsy.
    • Changed the dose of oral anti-spasticity medications within 2 weeks prior to study consent, or received botulinum toxin injections in the affected arm within 4 months prior to study consent, and/or plans to start anti-spasticity medications or botulinum toxin injections during the study follow-up period.
    • Presence of major active psychiatric illnesses that may interfere with treatment, such as psychotic disorders or severe personality disorders.
    • Untreated or inadequately treated depression, defined as a Beck Depression Inventory-II (BDI-II) score of ≥ 20 at enrollment.
    • Diagnosis of dementia.
    • Chronic uncontrolled hypertension, or a history of severe and uncontrolled cardiovascular disease.
    • Contraindications to Magnetic Resonance Imaging (MRI), such as body weight incompatible with the scanner, or implanted metallic/electronic devices (pacemakers, defibrillators, spinal cord stimulators, etc.).
    • Presence of severe and poorly controlled medical conditions which, in the opinion of the Principal Investigator (PI), would pose an expected risk higher than that of the general stroke population.
    • Currently participating in another device, biologic, or drug study, or has not completed one within 30 days prior to consenting to this study.
    • Pregnancy (women of childbearing potential must use acceptable methods of contraception).
    • History of hemicraniectomy.
    • History of cerebrovascular stent implantation.
    • Presence of significant chronic small vessel ischemic disease, vertebrobasilar vascular disease, and/or any other structural abnormalities in the cerebellum, cerebellar peduncles, or brainstem.
    • Any other condition that, in the opinion of the investigator, would significantly increase the risk of interfering with study compliance, safety, or outcomes.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Experimental: tTIS Intervention Group

All enrolled patients with chronic stroke will be assigned to this single arm to receive non-invasive temporal interference electrical stimulation (tTIS) therapy.

Patients will receive non-invasive temporal interference electrical stimulation targeting the contralateral cerebellar dentate nucleus. The stimulation is delivered with a total current of 6 mA. The treatment is administered 5 times a week for 4 consecutive weeks. Each treatment day includes two 40-minute tTIS sessions.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The safety of the tTIS intervention
Délai: Up to 4 weeks(from baseline to the end of treatment)

Safety will be evaluated by monitoring the incidence of adverse events (AEs), serious adverse events (SAEs), serious adverse device effects (SADEs), and unanticipated adverse device effects (UADEs) throughout the study period. An adverse event is defined as any untoward medical occurrence associated with the use of the intervention. A lower incidence (fewer participants experiencing AEs) indicates a better safety profile and therefore a better outcome.

Up to 4 weeks(from baseline to the end of treatment)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change from baseline in Upper Extremity Fugl-Meyer Assessment (FMA-UE) Score
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4

Upper limb motor function was assessed using the Upper Extremity Subscale of the Fugl-Meyer Assessment (FMA-UE), which has a total score range of 0 to 66. In this scale, a higher score indicates better upper limb motor function and therefore a better outcome, with 0 representing severe motor impairment and 66 representing normal motor function. Changes in the score reflect the degree of improvement in upper limb motor function.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Action Research Arm Test (ARAT) Score
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4

Upper limb functional limitation and dexterity were assessed using the Action Research Arm Test (ARAT), which has a total score range of 0 to 57. In this scale, a higher score indicates better arm motor function and therefore a better outcome, with 0 representing no movement possible and 57 representing normal performance. Changes in the score reflect the degree of improvement in upper limb function.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Lower Extremity Fugl-Meyer Assessment (FMA-LE) Score
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4

Lower limb motor function was assessed using the Lower Extremity Subscale of the Fugl-Meyer Assessment (FMA-LE), which has a total score range of 0 to 34. In this scale, a higher score indicates better lower limb motor function and therefore a better outcome, with 0 representing severe motor impairment and 34 representing normal motor function. Changes in the score reflect the degree of improvement in lower limb motor function.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Berg Balance Scale (BBS) Score
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4

Static and dynamic balance abilities were assessed using the Berg Balance Scale (BBS), which has a total score range of 0 to 56. In this scale, a higher score indicates better balance function and therefore a better outcome, with 0 representing severely impaired balance and 56 representing excellent balance. Changes in the score reflect the degree of improvement in balance and fall risk reduction.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Modified Barthel Index (MBI)
Délai: Baseline and Week 4

The patient's performance in activities of daily living was assessed using the Modified Barthel Index (MBI), which has a total score range of 0 to 100. In this scale, a higher score indicates a higher degree of independence in daily life and therefore a better outcome, with 0 representing complete dependence and 100 representing complete independence. Changes in the score reflect the degree of improvement in daily living abilities.

Baseline and Week 4
Change from baseline in Modified Ashworth Scale (MAS) Score
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4

Muscle spasticity was assessed using the Modified Ashworth Scale (MAS), which has a total score range of 0 to 4 (scored as 0, 1, 1+, 2, 3, 4). In this scale, a higher score indicates greater severity of muscle spasticity and therefore a worse outcome, with 0 representing no increase in muscle tone and 4 representing the affected part being rigid in flexion or extension. Changes in the score reflect the degree of improvement in muscle spasticity.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Brunnstrom Recovery Stages
Délai: Baseline, Week 1, Week 2, Week 3, and Week 4

The motor recovery process after stroke was assessed using the Brunnstrom Motor Recovery Stages, which classifies recovery into a range of Stage I to Stage VI (mapped to scores 1 to 6). In this scale, a higher stage indicates better voluntary motor control and therefore a better outcome, with Stage I representing flaccidity (no voluntary movement) and Stage VI representing near-normal joint movements. Changes in the stage reflect the progression of motor recovery.

Baseline, Week 1, Week 2, Week 3, and Week 4
Change from baseline in Mini-Mental State Examination (MMSE) Score
Délai: Baseline and Week 4

Cognitive function was assessed using the Mini-Mental State Examination (MMSE), which has a total score range of 0 to 30. In this scale, a higher score indicates better cognitive performance and therefore a better outcome, with 0 representing severe cognitive impairment and 30 representing normal cognition. Changes in the score reflect the degree of improvement in cognitive function.

Baseline and Week 4
Change from baseline in Montreal Cognitive Assessment (MoCA) Score
Délai: Baseline and Week 4

Mild cognitive dysfunction was assessed using the Montreal Cognitive Assessment (MoCA), which has a total score range of 0 to 30. In this scale, a higher score indicates better cognitive performance and therefore a better outcome, with 0 representing severe cognitive impairment and 30 representing normal cognition. Changes in the score reflect the degree of improvement in cognitive function.

Baseline and Week 4
Change from baseline in Hamilton Depression Rating Scale (HAMD) Score
Délai: Baseline and Week 4

The severity of depressive symptoms was assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), which has a total score range of 0 to 52. In this scale, a higher score indicates greater severity of depression and therefore a worse outcome, with 0 representing no depression and 52 representing the most severe depression. Changes in the score reflect the degree of improvement in depressive symptoms.

Baseline and Week 4
Change from baseline in Hamilton Anxiety Rating Scale (HAMA) Score
Délai: Baseline and Week 4

The severity of anxiety symptoms was assessed using the Hamilton Anxiety Rating Scale (HAMA), which has a total score range of 0 to 56. In this scale, a higher score indicates greater severity of anxiety and therefore a worse outcome, with 0 representing no anxiety and 56 representing the most severe anxiety. Changes in the score reflect the degree of improvement in anxiety symptoms.

Baseline and Week 4

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

1 janvier 2027

Achèvement de l'étude (Estimé)

15 janvier 2027

Dates d'inscription aux études

Première soumission

15 novembre 2026

Première soumission répondant aux critères de contrôle qualité

16 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner